Exelixis (EXEL) Down 2.8% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 03/12/26
Exelixis, Inc. (EXEL) Presents at Barclays 28th Annual Global Healthcare Conference TranscriptSeeking Alpha • 03/11/26
Exelixis, Inc. (EXEL) Presents at The Citizens Life Sciences Conference 2026 TranscriptSeeking Alpha • 03/11/26
Exelixis, Inc. (EXEL) Presents at Leerink Global Healthcare Conference 2026 TranscriptSeeking Alpha • 03/10/26
Exelixis, Inc. (EXEL) Presents at TD Cowen 46th Annual Health Care Conference TranscriptSeeking Alpha • 03/04/26
3 Reasons Exelixis Stock Could Deliver Market‑Beating Returns Over the Next DecadeThe Motley Fool • 02/28/26
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in MarchBusiness Wire • 02/24/26
Exelixis: The Cash‑Generating Biotech That I Think Deserves a Closer Look in 2026The Motley Fool • 02/20/26
A Dive into Exelixis (EXEL) International Revenue Trends and ForecastsZacks Investment Research • 02/16/26
EXEL Q4 Earnings and Revenues Beat, Colorectal Cancer Drug in FocusZacks Investment Research • 02/11/26
Compared to Estimates, Exelixis (EXEL) Q4 Earnings: A Look at Key MetricsZacks Investment Research • 02/11/26
Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate UpdateBusiness Wire • 02/10/26
2 Intriguing Medical Stocks to Watch as Q4 Results Approach: EXEL, GILDZacks Investment Research • 02/10/26
3 Reasons Why Growth Investors Shouldn't Overlook Exelixis (EXEL)Zacks Investment Research • 02/05/26
Exelixis (EXEL) Reports Next Week: Wall Street Expects Earnings GrowthZacks Investment Research • 02/03/26
Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal CancerBusiness Wire • 02/02/26